PPD Opens Office in Istanbul, Turkey

Strengthens company's presence in Eastern Europe
WILMINGTON, N.C.--(Business Wire)--
PPD, Inc. (Nasdaq: PPDI) today announced the opening of an office
in Istanbul, Turkey, continuing the company's growth of its Phase
II-IV clinical development services in Eastern Europe. PPD will
provide clinical monitoring services in key therapeutic areas from
this location.

The new office strengthens PPD's presence in Eastern Europe beyond
Russia and Ukraine, countries where the company is expanding through
its pending acquisition of InnoPharm Ltd. Eastern Europe is an
important, high-growth market for clinical trials and a region PPD has
targeted for expansion.

"With a population of 74 million people, Turkey is becoming an
attractive place to conduct clinical trials," said Fred Eshelman,
chief executive officer of PPD. "Eastern Europe offers recruitment
opportunities and quality investigators, and our Istanbul office is an
important part of our strategic growth in this region. We plan to
continue to expand in areas where there is high demand for our global
experience and therapeutic expertise."

The office is located at Perdemsac Plaza, Bavar Caddesi, Gulbahar
Sokak 17, Kat: 10 106-107-108-109, Kozyatagi 81090, Istanbul, Turkey.
For more information about PPD services provided from the Istanbul
office, call +44 1223 374430.

PPD is a leading global contract research organization providing
discovery, development and post-approval services as well as compound
partnering programs. Our clients and partners include pharmaceutical,
biotechnology, medical device, academic and government organizations.
With offices in 31 countries and more than 10,400 professionals
worldwide, PPD applies innovative technologies, therapeutic expertise
and a commitment to quality to help its clients and partners maximize
returns on their R&D investments and accelerate the delivery of safe
and effective therapeutics to patients. For more information, visit
our Web site at http://www.ppdi.com.

Except for historical information, all of the statements,
expectations and assumptions contained in this news release, including
expectations and assumptions about the opening of a new office and our
globalization strategy, are forward-looking statements that involve a
number of risks and uncertainties. Although PPD attempts to be
accurate in making these forward-looking statements, it is possible
that future circumstances might differ from the assumptions on which
such statements are based. In addition, other important factors which
could cause results to differ materially include the following:
continued success in sales growth; loss of large contracts; increased
cancellation rates; economic conditions and outsourcing trends in the
pharmaceutical, biotechnology, medical device, academic and government
industry segments; competition within the outsourcing industry; the
ability to attract and retain key personnel; risks associated with and
dependence on collaborative relationships; risks associated with the
development and commercialization of drugs, including earnings
dilution and obtaining regulatory approval; risks associated with
acquisitions and investments, such as impairments; rapid technological
advances that make our products and services less competitive; risks
that we may not continue our dividend policy; and the other risk
factors set forth from time to time in the SEC filings for PPD, copies
of which are available free of charge upon request from the PPD
investor relations department.

PPD, Inc.
Media: Sue Ann Pentecost, 1-919-456-5890
sueann.pentecost@rtp.ppdi.com
or
Analysts/Investors: Craig Eastwood, 1-910-558-7585
craig.eastwood@wilm.ppdi.com

Copyright Business Wire 2008